24 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp02160 | C7A | KILRGVAKKIMRTFLRRISKDILTGKK | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 :10.6 ± 0.4 µM |
| dbacp02161 | C7A | KILRGVAKKIMRTFLRRISKDILTGKK | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 :13.0 ± 1.0 µM |
| dbacp02162 | C7A | KILRGVAKKIMRTFLRRISKDILTGKK | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 :12.1 ± 1.6 µM |
| dbacp02163 | C7A | KILRGVAKKIMRTFLRRISKDILTGKK | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 :37 ± 4.3 µM |
| dbacp02181 | C7A-D21K | KILRGVAKKIMRTFLRRISKKILTGKK | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : 8.4 ± 0.2 µM |
| dbacp02182 | C7A-D21K | KILRGVAKKIMRTFLRRISKKILTGKK | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : 12.3 ± 2.0 µM |
| dbacp02183 | C7A-D21K | KILRGVAKKIMRTFLRRISKKILTGKK | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : 8.3 ± 0.5 µM |
| dbacp02184 | C7A-D21K | KILRGVAKKIMRTFLRRISKKILTGKK | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : 12.3 ± 1.0 µM |
| dbacp02206 | C7A-Δ | KILRGVAKKIMRTFLRRILTGKK | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : 13.8 ± 2.0 µM |
| dbacp02207 | C7A-Δ | KILRGVAKKIMRTFLRRILTGKK | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : 9.3 ± 1.5 µM |
| dbacp02208 | C7A-Δ | KILRGVAKKIMRTFLRRILTGKK | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : 13.1 ± 0.9 µM |
| dbacp02222 | C7A-Δ | KILRGVAKKIMRTFLRRILTGKK | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : 7.5 ± 0.4 µM |
| dbacp04643 | Melittin | GIGAVLKVLTTGLPALISWIKRKRQQ | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 :3.2 ± 0.1 µM |
| dbacp04644 | Melittin | GIGAVLKVLTTGLPALISWIKRKRQQ | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 :2.1 ± 0.1 µM |
| dbacp04645 | Melittin | GIGAVLKVLTTGLPALISWIKRKRQQ | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 :1.8 ± 0.1 µM |
| dbacp04646 | Melittin | GIGAVLKVLTTGLPALISWIKRKRQQ | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 :1.4 ± 0.1 µM |
| dbacp04855 | NK-2 | KILRGVCKKIMRTFLRRISKDILTGKK | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : 70 µM |
| dbacp04856 | NK-2 | KILRGVCKKIMRTFLRRISKDILTGKK | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : 50 µM |
| dbacp04857 | NK-2 | KILRGVCKKIMRTFLRRISKDILTGKK | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : 50 µM |
| dbacp04858 | NK-2 | KILRGVCKKIMRTFLRRISKDILTGKK | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : 40 µM |
| dbacp04880 | NK11 | KISKRILTGKK | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : >100 µM |
| dbacp04881 | NK11 | KISKRILTGKK | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : >100 µM |
| dbacp04882 | NK11 | KISKRILTGKK | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : >100 µM |
| dbacp04883 | NK11 | KISKRILTGKK | Synthetic peptide | Physical membrane disruption | MTT/MTS assay | E42/02 | Skin cancer | IC50 : >100 µM |